Fresenius SE Operating Income 2016-2023 | FSNUY
Fresenius SE annual/quarterly operating income history and growth rate from 2016 to 2023. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
- Fresenius SE operating income for the quarter ending September 30, 2023 was $0.377B, a 57.85% decline year-over-year.
- Fresenius SE operating income for the twelve months ending September 30, 2023 was $2.508B, a 38.73% decline year-over-year.
- Fresenius SE annual operating income for 2022 was $3.499B, a 28.87% decline from 2021.
- Fresenius SE annual operating income for 2021 was $4.919B, a 1.79% decline from 2020.
- Fresenius SE annual operating income for 2020 was $5.009B, a 3.43% decline from 2019.
Fresenius SE Annual Operating Income
(Millions of US $) |
| 2022 |
$3,499 |
| 2021 |
$4,919 |
| 2020 |
$5,009 |
| 2019 |
$5,187 |
| 2018 |
$6,201 |
| 2017 |
$5,187 |
| 2016 |
$4,788 |
| 2015 |
$4,303 |
Fresenius SE Quarterly Operating Income
(Millions of US $) |
| 2023-09-30 |
$377 |
| 2023-06-30 |
$592 |
| 2023-03-31 |
$845 |
| 2022-12-31 |
$694 |
| 2022-09-30 |
$893 |
| 2022-06-30 |
$899 |
| 2022-03-31 |
$1,012 |
| 2021-12-31 |
$1,288 |
| 2021-09-30 |
$1,189 |
| 2021-06-30 |
$1,230 |
| 2021-03-31 |
$1,213 |
| 2020-12-31 |
$1,230 |
| 2020-09-30 |
$1,301 |
| 2020-06-30 |
$1,237 |
| 2020-03-31 |
$1,241 |
| 2019-12-31 |
$1,408 |
| 2019-09-30 |
$1,255 |
| 2019-06-30 |
$1,257 |
| 2019-03-31 |
$1,266 |
| 2018-12-31 |
$1,400 |
| 2018-09-30 |
$1,210 |
| 2018-06-30 |
$2,317 |
| 2018-03-31 |
$1,273 |
| 2017-12-31 |
$1,298 |
| 2017-09-30 |
$1,309 |
| 2017-06-30 |
$1,284 |
| 2017-03-31 |
$1,296 |
| 2016-12-31 |
$1,346 |
| 2016-09-30 |
$1,197 |
| 2016-06-30 |
$1,187 |
| 2016-03-31 |
$1,058 |
| 2015-12-31 |
$7,951 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$16.392B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
